BACKGROUND: To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated data from the phase III CheckMate 9LA trial with a 2-year minimum follow-up. PATIENTS AND METHODS: Adult patients were treatment naïve, with stage IV/recurrent non-small-cell lung cancer, no known sensitizing EGFR/ALK alterations, and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with two cycles of chemotherapy, or four cycles of chemotherapy. Updated efficacy and safety outcomes are reported, along with progression-free survival (PFS) after next line of treatment (PFS2), treatment-related adverse events (TRAEs) by treatment cycle, and efficacy outcomes in patients who discontinued all treatment components in the experimental arm due to TRAEs. RESULTS: With a median follow-up of 30.7 months, nivolumab plus ipilimumab with chemotherapy continued to prolong overall survival (OS) versus chemotherapy. Median OS was 15.8 versus 11.0 months [hazard ratio 0.72 (95% confidence interval 0.61-0.86)]; 2-year OS rate was 38% versus 26%. Two-year PFS rate was 20% versus 8%. ORR was 38% versus 25%, respectively; 34% versus 12% of all responses were ongoing at 2 years. Median PFS2 was 13.9 versus 8.7 months. Improved efficacy outcomes in the experimental versus control arm were observed across most subgroups, including by programmed death-ligand 1 and histology. No new safety signals were observed; onset of grade 3/4 TRAEs was mostly observed during the first two treatment cycles in the experimental arm. In patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy treatment due to TRAEs (n = 61) median OS was 27.5 months; 56% of responders had an ongoing response ≥1 year after discontinuation. CONCLUSIONS: With a 2-year minimum follow-up, nivolumab plus ipilimumab with two cycles of chemotherapy provided durable efficacy benefits over chemotherapy with a manageable safety profile and remains an efficacious first-line treatment of advanced non-small-cell lung cancer.
- Reck, M.
- Ciuleanu, T. E.
- Cobo, M.
- Schenker, M.
- Zurawski, B.
- Menezes, J.
- Richardet, E.
- Bennouna, J.
- Felip, E.
- Juan-Vidal, O.
- Alexandru, A.
- Sakai, H.
- Lingua, A.
- Reyes, F.
- Souquet, P. J.
- De Marchi, P.
- Martin, C.
- Pérol, M.
- Scherpereel, A.
- Lu, S.
- Paz-Ares, L.
- Carbone, D. P.
- Memaj, A.
- Marimuthu, S.
- Zhang, X.
- Tran, P.
- John, T.
Keywords
- Nsclc
- dual immunotherapy
- first-line
- ipilimumab
- nivolumab
- Ingelheim, Bristol Myers Squibb, Eli Lilly, Mirati Therapeutics, MSD Oncology,
- Novartis, Pfizer, Roche/Genentech, and Samsung Bioepis
- speaker fees from Amgen,
- AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Merck
- Serono, Mirati Therapeutics, MSD Oncology, Novartis, Pfizer, and Roche/Genentech.
- TEC reports advisory/consulting fees and travel, accommodation, and expenses from
- Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Ipsen,
- Janssen, Merck Sharp & Dohme (MSD), Novartis/GlaxoSmithKline, Pfizer, Roche, Sanofi,
- and Servier. MS reports research funding from AbbVie, Amgen, Astellas Pharma,
- AstraZeneca, Bristol Myers Squibb, Clovis, Eli Lilly, Gilead Sciences,
- GlaxoSmithKline, MSD, Novartis, Pfizer/EMD Serono, Regeneron, Roche, and Tesaro
- travel, accommodation, and expenses from Bristol Myers Squibb. BZ reports research
- funding from Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline,
- Janssen-Cilag, MSD, and Roche. JB reports advisory/consulting fees and honoraria
- from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Roche, and
- Servier
- travel, accommodation, and expenses from AstraZeneca and Roche. EF reports
- advisory fees from AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Blue Print Medicines,
- Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen,
- Medical Trends, Merck KGaA, MSD, Novartis, Peptomyc, Pfizer, Puma Biotechnology,
- Regeneron, Roche, Sanofi Genzyme, Syneos Health, Takeda
- independent board member of
- Grifols
- research funding from Grant for Oncology Innovation and Fundación Merck
- Salud
- speaker fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb,
- Eli Lilly, Medscape, MSD, Novartis, PeerVoice, Pfizer, Prime Oncology, Roche,
- Springer, Takeda, Touch Medical, and CME Outfitters. OJV reports advisory/consulting
- fees from Boehringer Ingelheim, Bristol Myers Squibb, Lilly, MSD, Roche/Genetech,
- and Takeda
- honoraria from AstraZeneca/MedImmune, Bristol Myers Squibb, MSD
- Oncology, and Roche/Genentech
- research funding from AstraZeneca Spain
- speaker fees
- from Roche/Genentech
- travel, accommodation, and expenses from Boehringer Ingelheim,
- Bristol Myers Squibb, MSD, and Roche/Genentech. AA reports advisory/consulting fees
- from Boehringer Ingelheim Pharmaceuticals Inc and Roche
- expert testimony fees for
- AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Roche, and Sanofi
- speaker fees from Bristol Myers Squibb, Novartis, and Sandoz
- travel, accommodation,
- and expenses from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer,
- Roche, and Sanofi. HS reports research funding from AstraZeneca, Bristol Myers
- Squibb, Chugai Pharma, Merck KGaA, MSD K.K, Ono Pharmaceutical, and Taiho
- Pharmaceutical
- speaker fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers
- Squibb Japan, Chugai Pharma, MSD K.K, Ono Pharmaceutical, and Taiho Pharmaceutical.
- FR reports consulting and speaker fees from Novartis
- travel, accommodation, and
- expenses from Roche. PJS reports non-financial support from AstraZeneca, Bristol
- Myers Squibb, MSD, and Roche
- personal fees from AstraZeneca, Bristol Myers Squibb,
- Novartis, and Roche
- research funding from AstraZeneca, Bristol Myers Squibb,
- Novartis, MSD, and Roche. CM reports advisory and speaker fees from AstraZeneca,
- Bristol Myers Squibb, and MSD. MP reports advisory fees from AstraZeneca, Boehringer
- Ingelheim, Bristol Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, and
- Takeda
- research funding from AstraZeneca, Boehringer Ingelheim, Chugai, Roche, and
- Takeda
- speaker fees from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers
- Squibb, Chugai, Eli Lilly, MSD, Pfizer, Roche, and Takeda
- travel support from
- AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Eli Lilly, MSD,
- Pfizer, Roche, and Takeda. AS reports expert testimony fees from
- AstraZeneca/MedImmune, Bristol Myers Squibb, MSD Oncology, and Roche
- research
- funding from Bristol Myers Squibb
- speaker fees from AstraZeneca/MedImmune
- travel,
- accommodation, and expenses from AstraZeneca/MedImmune, Bristol Myers Squibb, MSD
- Oncology, and Roche. SL reports advisory/consulting fees from AstraZeneca,
- Boehringer Ingelheim, Hutchison MediPharma, Roche, and Simcere
- research funding
- from AstraZeneca, Bristol Myers Squibb, Hutchison MediPharma, Heng Rui, and Roche
- speaker fees from AstraZeneca, Hanseng, and Roche. LPA reports honoraria from Amgen,
- AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, Celgene, Ipsen, Eli
- Lilly, Merck Serono, Mirati Therapeutics, MSD, Novartis, Pfizer, PharmaMar,
- Roche/Genentech, Sanofi, Servier, and Takeda
- leadership fees from Genomica and
- ALTUM Sequencing
- research funding from AstraZeneca, Bristol Myers Squibb, Kura
- Oncology, PharmaMar, and MSD
- speaker fees from Bristol Myers Squibb, Eli Lilly,
- Merck Serono, MSD Oncology, Pfizer, Roche/Genentech
- travel, accommodation, and
- expenses from AstraZeneca, Bristol Myers Squibb, MSD, Pfizer, Roche, and Takeda. DPC
- reports advisory/consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, Boehringer
- Ingelheim, Bristol Myers Squibb, Bristol Myers Squibb Japan, Curio Science, Daiichi
- Sankyo, Eli Lilly, EMD Serono, Flame Biosciences, G1 Therapeutics (Intellisphere),
- Geneplus, GlaxoSmithKline, Gloria Biosciences, Incyte, Inivata, Inovio
- Pharmaceutical, Janssen, Johnson & Johnson, Kyowa Hakko Kirin, Loxo, Merck, Merck
- KGaA, MSD, Novartis, Novocure, Oncocyte, OncoHost, Pfizer, Piper Sandler,
- Roche/Genentech, Sanofi, and Takeda
- employment with James Cancer Center
- honoraria
- from AstraZeneca and Nexus Pharmaceutical
- research funding from Bristol Myers
- Squibb. AM is an employee of and has stock ownership in Bristol Myers Squibb. SM is
- an employee of and has stock ownership in Bristol Myers Squibb
- was employed as a
- contractor by Sanofi (Rangam Consultants Inc)
- reports travel, accommodation, and
- expenses from Bristol Myers Squibb. XZ is an employee of Bristol Myers Squibb. PT is
- an employee of and has stock ownership in Bristol Myers Squibb. TJ reports
- advisory/consulting fees from AstraZeneca, AstraZeneca/MedImmune, Boehringer
- Ingelheim, Bristol Myers Squibb, Ignyta, Merck KGaA, MSD Oncology, Novartis, Pfizer,
- and Roche/Genentech
- honoraria from AstraZeneca/MedImmune, Bristol Myers Squibb, MSD
- Oncology, and Roche/Genentech
- travel, accommodation, and expenses from AstraZeneca,
- Boehringer Ingelheim, Bristol Myers Squibb, MSD, and Roche. All other authors have
- declared no conflicts of interest.
